{"nctId":"NCT00241644","briefTitle":"Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants","startDateStruct":{"date":"2005-10"},"conditions":["Infections, Rotavirus"],"count":2089,"armGroups":[{"label":"Rotarix 3-Dose Group","type":"EXPERIMENTAL","interventionNames":["Biological: Rotarix™"]},{"label":"Rotarix 2-Dose Group","type":"EXPERIMENTAL","interventionNames":["Biological: Rotarix™","Biological: Placebo"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Rotarix™","otherNames":["GSK Biologicals' HRV vaccine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.\n* A male or female child between, and including, 5 and 10 weeks of age at the time of the first study vaccination.\n* Written informed consent obtained from the parent or guardian of the subject who is of legal age\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* In South Africa, birth weight \\> 2000 grams or if weight unknown, gestation period \\> 36 weeks.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product\n* Planned administration of a vaccine not foreseen by the study protocol within 14 days before each dose of study vaccine(s) and ending 14 days after.\n* Chronic administration (defined as more than 14 days) of immunosuppressants since birth.\n* History of use of experimental rotavirus vaccine.\n* Previous routine vaccination except Bacille Calmette-Guérin (BCG), hepatitis B virus (HBV) and oral poliovirus (OPV) vaccination at birth\n* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract, intussusception or other medical condition determined to be serious by the investigator.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination\n* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.\n* Acute disease at the time of enrolment.\n* Gastroenteritis within 7 days preceding the first study vaccine administration\n* Previous confirmed occurrence of rotavirus gastroenteritis (RV GE).\n* A family history of congenital or hereditary immunodeficiency.\n* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.\n* History of any neurologic disorders or seizures.\n* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.","healthyVolunteers":true,"sex":"ALL","minimumAge":"5 Weeks","maximumAge":"10 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"167","spread":null},{"groupId":"OG003","value":"174","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"68","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"In South Africa, Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Severe Gastroenteritis of Any Cause","description":"Number of subjects with gastroenteritis (three or more looser than normal stools or watery stools within a day) that scored ≥ 11 on the 20-point Vesikari scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"122","spread":null},{"groupId":"OG002","value":"256","spread":null},{"groupId":"OG003","value":"178","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"142","spread":null},{"groupId":"OG003","value":"156","spread":null}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"159","spread":null},{"groupId":"OG003","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Drop Out","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.\n\nAn SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"111","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"199","spread":null},{"groupId":"OG002","value":"421","spread":null},{"groupId":"OG003","value":"246","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies in Initially Seronegative Subjects","description":"An initially seronegative subject is a subject whose IgA antibody concentration was below the assay cut-off value of 20 Units per milliliter (U/mL) before administration of the first vaccine dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null},{"groupId":"OG001","value":"79.4","spread":null},{"groupId":"OG002","value":"67.5","spread":null},{"groupId":"OG003","value":"23.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects","description":"Seroconverted subjects are defined as subjects with appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in subjects initially (i.e. prior to the first dose of vaccine or placebo) seronegative for rotavirus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"129","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies","description":"Geometric mean concentrations are given as Units per milliliter (U/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null},{"groupId":"OG001","value":"67.9","spread":null},{"groupId":"OG002","value":"70.2","spread":null},{"groupId":"OG003","value":"21.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects","description":"Seropositive subjects are defined as subjects with anti-rotavirus IgA antibody concentration ≥ 20 U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"756","spread":null},{"groupId":"OG001","value":"706","spread":null},{"groupId":"OG002","value":"1462","spread":null},{"groupId":"OG003","value":"262","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":222,"n":1647},"commonTop":[]}}}